Terra Biological is a leader in the discovery and development of a new class of therapeutic compounds that target the metabolic environment for treatment of mitochondrial-based diseases such as cancer, Alzheimer disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS). Established in 2006, the company has leveraged research into the cellular aging process to develop unique, small molecules that are designed to change gene expression and enhance metabolic processes. Terra Biological is a privately-held life sciences company based in San Diego, California.
David Conway oversees clinical trials at Terra Biological. Mr Conway has over 25 years of professional experience in the Pharmaceutical, Biopharmaceutical, and Medical Diagnostic industry. This includes experience in clinical research, development, and clinical operations. Mr Conway’s experience includes direct managerial responsibility for Clinical and Medical Operations Departments in US and Europe with direct responsibility for clinical studies, project management of US and European clinical studies, management of clinical research personnel, and direct hands-on experience in the writing of IBs, protocols, CRF’s, statistical analysis plans, Clinical Study Reports, IND’s, BLA’s/NDA’s, Type B and C Meeting Briefing Books, pre IDEs, and CE Mark applications. Mr Conway has directed coordination of large multi-national pivotal clinical studies that have led to the approval of several novel drugs, drug applications and diagnostic devices. This includes HYQVIA, MabThera SC, Herceptin SC, Anzemet®, Infergen®, NGAL CE Mark, and Nutre-Store L-Glutamine® Mr Conway has a BS in Microbiology from Colorado State University, MS Pharm. from University of Missouri-Kansas City and MT(ASCP) from The Trinity Lutheran Hospital in Kansas City, MO. He is also an invited speaker to numerous industry conferences on a wide range of topics dealing with clinical and medical operations.
Alan Cash serves as founder and chief science officer at Terra Biological. Researching into the molecular and genomic mechanisms of aging and the effects of calorie restriction on aging, Mr. Cash developed unique molecular methods and compounds to mimic calorie restriction and extend lifespan in laboratory animals. The same science is being examined for a variety of human diseases. Mr. Cash has an MS in physics from the University of Oklahoma. As an entrepreneur Mr. Cash has gained recognition and awards from the White House, INC 500 business, Ernst & Young Entrepreneur of the Year, Deloitte and Touche Technology Fast 50, and Top 100 Hotfirm.
Kathy Cash serves as the firm’s sales and marketing manager. Ms. Cash has extensive pharmaceutical sales and marketing experience, working with Bristol-Meyers Squibb, Boehringer Mannheim, and Blue Cross/Blue Shield. She has been recognized as a top sales leader by all of her employers. She holds a BS from Oklahoma State University.